Abstracts tagged "rheumatoid arthritis"

Abstract Number: 2100 • ACR Convergence 2023
Paradoxical Antagonistic Association of Visceral and Subcutaneous Adipose Tissue with Circulating C-Reactive Protein in Rheumatoid Arthritis
Jon Giles and Joan Bathon, Columbia University, New York, NY
Background/Purpose: C-reactive protein (CRP) is used as an indicator of disease activity in people with RA.However, adipose tissue also expresses inflammatory cytokines that induce hepatic…
Abstract Number: 2117 • ACR Convergence 2023
Frailty Is Associated with Mortality in Veterans with Rheumatoid Arthritis
Sayuli Bhide¹, Punyasha Roul², Namrata Singh³, Grant Cannon⁴, Gary Kunkel⁵, Ted R Mikuls⁶, Bryant England², Dolores Shoback⁷, Patti Katz⁸, Jose Garcia⁹, Ariela Orkaby¹⁰, Joshua Baker¹¹ and K Wysham¹², ¹University of Washington, Seattle, WA, ²University of Nebraska Medical Center, Omaha, NE, ³University of Washington, Bellevue, WA, ⁴University of Utah and Salt Lake City VA, Salt Lake City, UT, ⁵University of Utah, Salt Lake City, UT, ⁶Division of Rheumatology and Immunology, University of Nebraska Medical Center, Omaha, NE, ⁷San Francisco VA Medical Center, San Francisco, CA, ⁸University of California San Francisco, San Rafael, CA, ⁹VA Puget Sound Healthcare System, Seattle, WA, ¹⁰Veterans Affairs Boston Healthcare System & Brigham and Women’s Hospital, Harvard Medical School, Boston, MA; VA Geriatric Research Education and Clinical Center, Boston, MA, ¹¹University of Pennsylvania, Philadelphia, PA, ¹²VA Puget Sound/University of Washington, Seattle, WA
Background/Purpose: Frailty is established as an important predictor of mortality in the general population.1Rheumatoid arthritis (RA) is associated with higher rates of frailty than the…
Abstract Number: 2133 • ACR Convergence 2023
Cardiovascular Risk Factors Are Associated with Discontinuation of Advanced Therapies Due to Treatment Failure in Rheumatoid Arthritis: Results from the OBRI
Samar Aboulenain¹, Xiuying Li², Mohammad Movahedi³, Claire Bombardier¹ and Bindee Kuriya¹, ¹University of Toronto, Toronto, ON, Canada, ²Toronto General Hospital, Toronto, ON, Canada, ³Toronto General Hospital Research Institute, University Health Network, Toronto, ON, Canada
Background/Purpose: Cardiovascular (CVD) comorbidity can impact overall RA care. We demonstrated that CVD risk factors were associated with higher disease activity and disability. Here, we…
Abstract Number: 2149 • ACR Convergence 2023
Biologic IRL201805 Drives Differential Cell-contact and Metabolism Transcriptional Profiles in Monocytes from RA Patients Compared to Healthy Donors
Yuriko Yamamura¹, Kieran Woolcock², Valerie Corrigall³, Lara Ravanetti⁴, Jorge De Alba⁴, Roly Foulkes⁵, Paul Eggleton⁶ and Carl Goodyear², ¹School of Infection & Immunity, University of Glasgow, Glasgow, United Kingdom, ²University of Glasgow, Glasgow, United Kingdom, ³Revolo Biotherapeutics, Tadworth, United Kingdom, ⁴Revolo Biotherapeutics, London, United Kingdom, ⁵Revolo Biotherapeutics, Slough, United Kingdom, ⁶Revolo Biotherapeutics, Exeter, United Kingdom
Background/Purpose: IRL201805 is a novel biologic derived from Binding Immunoglobulin Protein (BiP) that has been developed for the treatment of Rheumatoid arthritis (RA) (P Eggleton,…
Abstract Number: 2166 • ACR Convergence 2023
Long-Term Effects of Abatacept on Arthritis and Atherosclerosis in Older vs Younger Patients with Rheumatoid Arthritis: 3-year Results of a Prospective, Multicenter, Observational Study
Zento Yamada¹, Sei Muraoka¹, Mai Kawazoe², Wataru Hirose³, Hajime Kono⁴, Shinsuke Yasuda⁵, Takahiko Sugihara⁶ and Toshihiro Nanki², ¹Division of Rheumatology, Department of Internal Medicine, Toho University School of Medicine, Tokyo, Japan, ²Division of Rheumatology, Department of Internal Medicine, Toho University School of Medicine, Ota-ku, Japan, ³Hirose Clinic of Rheumatology, Saitama, Japan, ⁴Teikyo University School of Medicine, Tokyo, Japan, ⁵Department of Rheumatology, Graduate School of Medical and Dental Science, Tokyo Medical and Dental University (TMDU), Tokyo, Japan, ⁶Toho University, Tokyo, Japan
Background/Purpose: Patients with rheumatoid arthritis (RA) are at an increased risk of cardiovascular disease secondary to atherosclerosis. Although it has been reported that TNF inhibitor…
Abstract Number: 2434 • ACR Convergence 2023
Acetylated Bacterial Proteins as Potent Antigens Inducing an Anti-modified Protein Antibody Response
Mikhail Volkov, Arieke Kampstra, Karin van Schie, Joanneke Kwekkeboom, Arnoud de Ru, Peter van Veelen, Thomas Huizinga, René Toes and Diane van der Woude, Leiden University Medical Center, Leiden, Netherlands
Background/Purpose: Gut-residing bacteria, such as E.coli, can acetylate their proteome under conditions of amine starvation. It is postulated that the (gut) microbiome is involved in…
Abstract Number: 2507 • ACR Convergence 2023
ZCCHC6 Modulates the Global Phosphorylation Landscape in TNF-a-induced Rheumatoid Arthritis Synovial Fibroblasts
Anil Singh, Farheen Sultan Shaikh and Salahuddin Ahmed, Washington State university, Spokane, WA
Background/Purpose: ZCCHC6, also known as TUT7 or TENT2, plays a crucial role in RNA processing and metabolism through its uridylyl transferase function. This function involves…
Abstract Number: 2592 • ACR Convergence 2023
Trends, Sociodemographic and Clinical Factors Associated with Avascular Necrosis and Related Arthroplasties in Hospitalized Patients with Systemic Lupus Erythematosus and Rheumatoid Arthritis
Rashmi Dhital¹, Neha Singh², Brian Pedersen² and Christie M. Bartels³, ¹UC San Diego, San Diego, CA, ²University of California San Diego, San Diego, CA, ³University of Wisconsin, School of Medicine and Public Health, Madison, WI
Background/Purpose: Avascular necrosis (AVN) can be a debilitating complication of autoimmune diseases and steroid treatment, with a higher prevalence in systemic lupus erythematosus (SLE) (0.8-33%)…
Abstract Number: 0012 • ACR Convergence 2023
Immune-cell Derived Cytokines Synergistically Interact to Drive Synovial Fibroblast Invasive Function and Metabolic Capacity
Órla Tynan¹, Achilleas Floudas², Nuno Neto³, Michael Monaghan³, Siobhán Wade⁴, Dumitru Anton⁵, Carl Orr⁶, Douglas Veale⁷ and Ursula Fearon⁸, ¹Molecular Rheumatology Department, Trinity Biomedical Sciences Institute, Trinity College Dublin, Ireland, EULAR Centre for Arthritis and Rheumatic Diseases, St Vincent University Hospital, University College Dublin, Dublin, Ireland, ²Dublin City University, Dublin, Ireland, ³Department of Mechanical and Manufacturing Engineering, Trinity College Dublin, Dublin, Ireland, ⁴Molecular Rheumatology Department, Trinity Biomedical Sciences Institute, Trinity College Dublin, Ireland EULAR Centre for Arthritis and Rheumatic Diseases, St Vincent University Hospital, University College Dublin, Dublin, Ireland, ⁵Molecular Rheumatology Department, Trinity Biomedical Sciences Institute, Trinity College Dublin, EULAR Centre for Arthritis and Rheumatic Diseases, St Vincent University Hospital, University College Dublin, Dublin, Ireland, ⁶EULAR Centre for Arthritis and Rheumatic Diseases, St Vincent University Hospital, University College Dublin, Dublin, Ireland, ⁷St.Vincent's University Hosp, Dublin, Ireland, ⁸Trinity College Dublin, Dublin, Ireland
Background/Purpose: Rheumatoid Arthritis (RA) and Psoriatic Arthritis (PsA) encompass two of the most common forms of Inflammatory Arthritis. While common pathogenic mechanisms are involved in…
Abstract Number: 0076 • ACR Convergence 2023
Characterizing GMCSF Producing T-cells in Rheumatoid Arthritis and Effect of Methotrexate on Them
AASTHA KHULLAR¹, Varun Dhir², Leishangthem Bidyalaxmi¹, Chandra Bhushan Prasad³, Sankar Jayaprakash¹, Siddharth Jain⁴, Biman Saikia¹, Aman Sharma⁵, Shefali Sharma⁶, Ashok Kumar Yadav¹, Shankar Naidu¹ and Sanjay Jain⁷, ¹PGIMER, Chandigarh, India, ²PGIMER, CHD, INDIA, Chandigarh, India, ³Healthway Hospital, Goa, Zuarinagar, India, ⁴AIIMS, Delhi, India, ⁵PGIMER, Chandigarh, India, Chandigarh, India, ⁶PGIMER< Chandigarh, Chandigarh, India, ⁷Post Graduate Institute of Medical Education and Research, Chandigarh, India
Background/Purpose: Background: GMCSF producing T-cells may be implicated in the pathogenesis of autoimmune diseases like rheumatoid arthritis (RA), multiple sclerosis (MS) and psoriatic arthritis. Few…
Abstract Number: 0206 • ACR Convergence 2023
Risk of Hepatitis B Virus Reactivation in Patients with Rheumatoid Arthritis Receiving JAK Inhibitor or IL-6 Inhibitor: A Systematic Review and Meta-Analysis
Akhil Sood, Janice Lin and Neha Shah, Stanford University, Palo Alto, CA
Background/Purpose: Due to the use of immunosuppressants, patients with rheumatic diseases are at increased risk for Hepatitis B virus (HBV) reactivation. B-cell depleting agents and…
Abstract Number: 0381 • ACR Convergence 2023
Disease Burden, Patient Experiences, and Unmet Needs in Refractory Rheumatoid Arthritis: Insights from 20 Years of Real-World Data
Kristin Wipfler¹, Bobby Kwanghoon Han², Sofia Pedro³, Urbano Sbarigia⁴, Federico Zazzetti⁵, Anna Sheahan⁶, Iris Lin⁷, Patti Katz⁸, Evo Alemao⁹ and Kaleb Michaud¹⁰, ¹FORWARD, The National Databank for Rheumatic Diseases, Omaha, NE, ²University of Washington, Seattle, WA, ³Forward, The National Databank for Rheumatic Diseases, Wichita, KS, ⁴Janssen Pharmaceutica, Beerse, Belgium, ⁵Janssen Research & Development, LLC, Spring House, PA, ⁶Janssen, Raleigh, NC, ⁷Janssen, Horsham, PA, ⁸University of California San Francisco, San Rafael, CA, ⁹Janssen Pharmaceuticals, New Hope, PA, ¹⁰University of Nebraska Medical Center, Omaha, NE
Background/Purpose: Despite major advances in RA treatment, a substantial number of patients (estimated at 6-21%1) are refractory to multiple advanced therapies. Well-defined refractory RA (reRA)…
Abstract Number: 0397 • ACR Convergence 2023
Obesity Is Associated with Worse Flare Symptoms and Quality of Life in Early Rheumatoid Arthritis: Insights from the RA Flare Questionnaire
Margaret Butler¹, Carlos Aude², Clifton Bingham³ and Vivian Bykerk¹, ¹Hospital for Special Surgery, New York, NY, ²Hospital for Special Surgery, Weill Cornell Medicine, New York, NY, ³Johns Hopkins University, Baltimore, MD
Background/Purpose: Elevated BMI has been previously associated with lower RA remission rates and underascertainment of swollen joint counts.1,2 However, a knowledge gap persists regarding the…
Abstract Number: 0414 • ACR Convergence 2023
Association of a Treat-to-Target Management Approach with Physician and Patient Reported Outcomes Among Real – World Patients with Rheumatoid Arthritis Receiving Advanced Therapy in Europe
Douglas White¹, Aditi Kadakia², Oliver Howell³, Sander Strengholt⁴, Emily Goddard³, Sophie Barlow³ and Tsutomu Takeuchi⁵, ¹Waikato Clinical School, University of Auckland, Hamilton, New Zealand, ²AbbVie, Inc., North Chicago, IL, ³Adelphi Real World, Bollington, United Kingdom, ⁴AbbVie B.V., Mijdrecht, Utrecht, Netherlands, ⁵Keio University School of Medicine and Saitama Medical University, Tokyo, Japan
Background/Purpose: Rheumatoid arthritis (RA) is an autoimmune disease affecting the joints, causing swelling, stiffness, and pain that impact a patient's quality of life. EULAR treatment…
Abstract Number: 0431 • ACR Convergence 2023
Senescence and Cell Exhaustion in CD4+ and CD8+ Lymphocytes in Rheumatoid Arthritis Patients in Remission Without Treatment
Rodolfo Jiménez-Soto¹, Luis llorente², Guadalupe Lima¹, Luisa Alanis Saenz¹, Amairani Gomez Rodriguez¹, Hilda Marin Lopez¹, Erik Cimé-Aké¹ and Juan Jakez-Ocampo¹, ¹Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico, ²Departamento de Inmunología y Reumatología, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico
Background/Purpose: T cells are important among the several risk factors and immunological markers implicated in rheumatoid arthritis (RA). The goal of this study was to…

All abstracts accepted to PRYSM are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 6:00 PM CT on March 18. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].